1. Home
  2. PLX vs HEQ Comparison

PLX vs HEQ Comparison

Compare PLX & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLX
  • HEQ
  • Stock Information
  • Founded
  • PLX 1993
  • HEQ 2011
  • Country
  • PLX United States
  • HEQ United States
  • Employees
  • PLX N/A
  • HEQ N/A
  • Industry
  • PLX Biotechnology: Biological Products (No Diagnostic Substances)
  • HEQ Investment Managers
  • Sector
  • PLX Health Care
  • HEQ Finance
  • Exchange
  • PLX Nasdaq
  • HEQ Nasdaq
  • Market Cap
  • PLX 127.4M
  • HEQ 127.8M
  • IPO Year
  • PLX 1998
  • HEQ N/A
  • Fundamental
  • Price
  • PLX $1.54
  • HEQ $10.58
  • Analyst Decision
  • PLX Strong Buy
  • HEQ
  • Analyst Count
  • PLX 1
  • HEQ 0
  • Target Price
  • PLX $15.00
  • HEQ N/A
  • AVG Volume (30 Days)
  • PLX 498.6K
  • HEQ 43.1K
  • Earning Date
  • PLX 08-14-2025
  • HEQ 01-01-0001
  • Dividend Yield
  • PLX N/A
  • HEQ 9.78%
  • EPS Growth
  • PLX N/A
  • HEQ N/A
  • EPS
  • PLX 0.05
  • HEQ N/A
  • Revenue
  • PLX $59,764,000.00
  • HEQ N/A
  • Revenue This Year
  • PLX $10.00
  • HEQ N/A
  • Revenue Next Year
  • PLX $83.13
  • HEQ N/A
  • P/E Ratio
  • PLX $32.18
  • HEQ N/A
  • Revenue Growth
  • PLX 0.18
  • HEQ N/A
  • 52 Week Low
  • PLX $0.82
  • HEQ $9.08
  • 52 Week High
  • PLX $3.10
  • HEQ $11.84
  • Technical
  • Relative Strength Index (RSI)
  • PLX 53.22
  • HEQ 54.29
  • Support Level
  • PLX $1.41
  • HEQ $10.36
  • Resistance Level
  • PLX $1.52
  • HEQ $10.68
  • Average True Range (ATR)
  • PLX 0.06
  • HEQ 0.07
  • MACD
  • PLX 0.01
  • HEQ 0.00
  • Stochastic Oscillator
  • PLX 56.52
  • HEQ 68.75

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: